HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011

Phase 2Withdrawn
0 watching 0 views this week Active
44
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Analgesia

Conditions

Analgesia

Trial Timeline

Jul 1, 2023 → Dec 1, 2025

About HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011

HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011 is a phase 2 stage product being developed by Heron Therapeutics for Analgesia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03922048. Target conditions include Analgesia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03922048Phase 2Withdrawn

Competing Products

20 competing products in Analgesia

See all competitors
ProductCompanyStageHype Score
AcetaminophenJohnson & JohnsonPhase 2
52
HRF2105 patch + Loxoprofen patch + placeboJiangsu Hengrui MedicinePhase 2
52
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
33
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
85
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
65
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
52
Org 28611 + morphine sulfate + PlaceboMerckPhase 2
52
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloridePfizerPhase 1
32
Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
76
HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
74
Experimental: stage I:HSK21542 0.4 μg/kg + Experimental: stage I:HSK21542 1 μg/kg + Experimental: stage I:HSK21542 0.5μg/kg + Experimental: stage I:HSK21542 1μg/kg + Experimental: stage II:HSK21542 0.5μg/kg + Experimental: stage II:HSK21542 1μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
49
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
74
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
69
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
77
HTX-011 + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 2
44
Bupivacaine HClHeron TherapeuticsApproved
77
HTX-011 + PlaceboHeron TherapeuticsPhase 2
44
HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3
69
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
77